IVVD Company Profile and Key Details

Invivyd, Inc. (NASDAQ:IVVD) closed at $0.89 USD, gaining $0.11 (13.53%) from the previous close of $0.79. The stock is currently mid-range between its 52-week high and low $0.53 and $3.07. With a market capitalization of about $262.73 million, Invivyd, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.71). Key stats such as the average daily volume over the past year has been around 4.42 million shares, in line with its 52-week average. Headquartered in New Haven, CT, Invivyd, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William E. Duke Jr., the company employs approximately 122 people and listed since August 06, 2021. Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases.

Invivyd, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.25. This means the shares are trading below this model’s fair value.

Short-term trend indicators are mixed aligned (SMA20 2.32%, SMA50 -19.26%, SMA200 16.05%). The stock’s 14-day RSI is 44.63 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.62% below its high and over 269.57% above its low. Average 10-day trading volume of 2.45 million shares is below the 3-month average of 4.40 million, indicating normal recent market interest.

Invivyd, Inc. generated EPS of -$0.47 over the past year. Five-year average earnings growth is -24.99%. Wall Street analysts project EPS growth of 48.75% annually over the next five years. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.08. Next year's EPS is expected at $49.19. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $2.00. The high target offers 1023.6% upside. The low target suggests 124.72% downside. The mean target is $9.38. This offers 953.93% upside. Invivyd, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 13, 2026, missed forecasts by 31.25%. The prior quarter beat by 62.5%. Over the last six quarters, Apple has recorded several small beats. These include 250.0% in May 15, 2025.

Invivyd, Inc. has 294.76 million shares outstanding. The public float is 207.83 million shares, elevated short interest at 10.43% of float. This equals 27.80 million shares. The short ratio is 8.33 days. Institutional investors hold 91.0% of the float. Insiders own 7.07%. Adimab, LLC holds 21.69 million shares, MCGUIRE TERRANCE has 3.07 million shares and Andersen Jill has 283.77 thousand shares. Over the past six months, insider transactions show net selling. They sold 228.02 thousand shares across 10 transactions.

Invivyd, Inc. trades at a P/E ratio of -2.32, slightly below the S&P 500 average, with a price-to-sales ratio of 4.62 and a price-to-book ratio of 1.62 suggesting the stock is closer to book value. The P/FCF stands at -2.46, also below market averages.

Our AI price prediction model suggests that Invivyd, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.85%, with price expected at $0.91 by September 25, 2026, within a range of $0.81 to $1.02 3-Month Outlook: Projected rise of 1.85%, reaching $0.80 by December 10, 2026, with a range of $0.68 to $0.89. 1-Year Outlook: Projected gain of 51.5%, with price at $1.19 by September 10, 2027, within a range of $0.00 to $0.00.

Invivyd, Inc. (NASDAQ:IVVD) shares are flat -9.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Invivyd, Inc. trading at a premium to the broader market with a P/E of -2.32. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.03, suggesting 922.28% upside. Our AI forecast model points to short-term strength (15.85% over two weeks), a medium-term rise (1.85% over three months), and a longer-term gain (51.5% over one year), with expected trading ranges indicating moderate volatility.